Bibliography
- Marcelli M, Cunningham GR. Hormonal signaling in prostatic hyperplasia and neoplasia. J Clin Endocrinol Metab 1999;84:3463-68
- Caine M. The present role of α-adrenergic blockers in the treatment of benign prostatic hypertrophy. J Urol 1986;136:1-4
- Nagle M. BioXell says ‘ciao’ to enlarged prostates. Available from: http://www drugresearcher com Last accessed [17 March 2008]
- Stoner E. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994;43:284-9
- Peehl DM, Skowronski RJ, Leung GK, et al. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 1994;54:805-10
- Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993;132:1952-60
- Wu-Wong JR, Tian J, Goltzman D. Vitamin D analogs as therapeutic agents: a clinical study update. Curr Opin Invest Drugs 2004;5:320-6
- Colli E, Rigatti P, Montrosi F, et al. BXL-628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur J Urol 2006;49:82-6
- McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Eng J Med 1998;338:557-63
- BioXell announces positive phase IIb results for elocalcitol in benign prostatic hyperplasia. Available from: http://www bioxell com/media/press-releases/ [Last accessed 17 March 2008]
- Crescioli C, Morelli A, Adorini L. Human bladder as a novel target for vitamin D receptor ligands. J Clin Endocrinol Metab 2005;90:962-72
- Adorini L, Penna G, Amuchastegui S, et al. Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). J Steroid Biochem Mol Biol 2007;103:689-93
- Crescioli C, Ferruzzi P, Caporali A, et al. Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostatic hyperplasia. Eur J Endocrinol 2004;150:591-603
- Tiwari A, Krishna NS, Nanda K, Chugh A. Benign prostatic hyperplasia: an insight into current investigational medical therapies. Expert Opin Invest Drugs 2005;14:1359-72